The nation of Zimbabwe has turned down a major American healthcare agreement valued at $367m (£272m) over five years due to the United States' request for sensitive information.
This move came to light after a official document from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "skewed".
An official representative has since stated that the United States was seeking genetic material for research and profit but was not willing to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further talks to find a deal agreeable to both sides so the country's critical HIV programme can proceed.
Wider Context
This development follows a comparable case in neighbouring Kenya, where a court blocked a related deal with the US after concerns were raised about the security of citizens' health data.
After returning to office last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to enhance openness and accountability.
Based on reports, Sixteen African countries have to date signed similar health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership could have provided immense benefits for Zimbabwean communities, especially the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to surrender its biological resources and data over an extended period, with no equivalent assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our nation would provide the raw materials for medical research without any assurance that the final treatments would be available to our population should a new pandemic emerge."
Sovereignty and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining structures already established through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This system is designed to ensure that when a nation provides its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how future co-operation might be designed in a manner that respects the sovereignty and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but suggested that negotiations need to persist considering a large portion of the country's Aids initiatives were funded by international support.
"Where specific concerns exist, including those involving data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it said.
This impasse emphasises the continuing debate between receiving much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.